| S2492 |
Novobiocin Sodium (Cathomycin, Albamycin)
|
Novobiocin Sodium (NSC 2382, Albamycin, Cathomycin) is an aminocoumarin antibiotic that targets bacterial DNA gyrase (TopoIV), used to treat susceptible gram positive bacteria.
|
-
Redox Biol, 2025, 85:103672
-
J Transl Med, 2025, 23(1):1079
-
Cancer Res Commun, 2025, 10.1158/2767-9764.CRC-24-0433
|
|
| S1082 |
Vismodegib (GDC-0449)
|
Vismodegib (GDC-0449) is a potent, novel and specific hedgehog inhibitor with IC50 of 3 nM and also inhibits P-gp with IC50 of 3.0 μM in a cell-free assay.
|
-
Nat Commun, 2025, 16(1):5137
-
Nat Commun, 2025, 16(1):1092
-
Nat Commun, 2025, 16(1):1267
|
|
| E7980 |
Fumitremorgin C
|
Fumitremorgin C is a potent and selective ABCG2/BRCP inhibitor.
|
|
|
| S1424 |
Prazosin HCl
|
Prazosin HCl (cp-12299-1) is a competitive alpha-1 adrenoceptor antagonist, used to treat high blood pressure or benign prostatic hyperplasia.
|
-
Communications Medicine, October 2025, 5(1)
-
Anticancer Research, December 2021, 6179-6190
-
Communications Medicine, 2025, 420
|
|
| S7043 |
Ko143
|
KO143 is a potent and relatively selective ATP-binding cassette sub-family G member 2 (ABCG2/BCRP) inhibitor. KO143 decreases the ATPase activity of ABCG2 with IC50 of 9.7 nM.
|
-
Cancer Science, November 29, 2025, e70282
-
Frontiers in Oncology, March 02, 2021, 620907
-
MedComm, 2025, e70517
|
|
| S1715 |
Glipizide
|
Glipizide (CP-28720,K 4024) is used to treat high blood sugar levels caused by a type of diabetes mellitus called type 2 diabetes.
|
-
Journal of Experimental & Clinical Cancer Research, 2025, 294
-
J Exp Clin Cancer Res, 2025, 44(1):294
-
Communications Medicine, 2025, 420
|
|
| S4166 |
Chlorpropamide
|
Chlorpropamide inhibits Na(+),K(+)-ATPase and stimulates a high affinity cyclic AMP-phosphodiesterase of isolated liver plasma membrane. Chlorpropamide is a sulfonylurea class drug for type 2 diabetes mellitus.
|
-
Cancer Biology & Medicine, January 15, 2022, 19(1):74-89
-
Nat Commun, 2017, 8(1):573
|
|
| S2119 |
Probucol
|
Probucol (DH-581) is an anti-hyperlipidemic drug by lowering the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism.
|
-
J Immunother Cancer, 2024, 12(11)e009805
-
Int Immunopharmacol, 2023, 116:109820
|
|
| E5770 |
DIDS sodium salt
|
|
-
Integrative Cancer Therapies, 2019, 1534735418822120
|
|
| E7972 |
Isosilybin A
|
Isosilybin A is a flavonolignan isolated from silymarin that exhibits anti-prostate cancer (PCA) efficacy with an IC50 of 32 μM in DU145 cells. It induces growth inhibition, G1 arrest, and apoptosis in PCA cells by targeting the Akt-NF-κB-AR axis, highlighting its potential as a therapeutic agent in clinical prostate cancer (PCA) management.
|
|
|